Vulcan Materials CO — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Vulcan Materials CO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $7.78B | Feb 22, 2024 |
| FY2023 | Dec 31, 2022 | $7.32B | Feb 22, 2024 |
| FY2023 | Dec 31, 2021 | $5.55B | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | $1.18B | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $1.31B | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $1.32B | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $1.05B | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $1.19B | Feb 25, 2021 |
| FY2020 | Sep 30, 2019 | $1.42B | Feb 25, 2021 |
| FY2020 | Jun 30, 2019 | $1.33B | Feb 25, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.94B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $7.42B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $7.78B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $7.32B | Feb 20, 2025 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $977.49M | Feb 27, 2018 |
| FY2017 | Sep 30, 2017 | $1.09B | Feb 27, 2018 |
| FY2017 | Jun 30, 2017 | $1.03B | Feb 27, 2018 |
| FY2017 | Mar 31, 2017 | $787.33M | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $872.97M | Feb 27, 2018 |
| FY2017 | Sep 30, 2016 | $1.01B | Feb 27, 2018 |
| FY2017 | Jun 30, 2016 | $956.83M | Feb 27, 2018 |
| FY2017 | Mar 31, 2016 | $754.73M | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | $857.29M | Feb 24, 2017 |
| FY2016 | Sep 30, 2015 | $1.04B | Feb 24, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.17B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.00B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.95B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.56B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.37B | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | $302.74M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $380.50M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $396.52M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $201.72M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $293.08M | Feb 25, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.08B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $911.90M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $933.20M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $575.60M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $670.80M | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | $114.52M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $199.79M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $209.92M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $60.26M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $141.09M | Feb 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.62B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.36B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.43B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $951.40M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.01B | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | $196.43M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $288.10M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $298.90M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $112.30M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $193.58M | Feb 25, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $0 | Feb 26, 2014 |
| FY2012 | Dec 31, 2012 | $0 | Feb 28, 2013 |
| FY2011 | Dec 31, 2011 | $1.11M | Feb 29, 2012 |
| FY2010 | Dec 31, 2010 | $1.58M | Feb 28, 2011 |
| FY2010 | Dec 31, 2009 | $1.54M | Feb 28, 2011 |
| FY2010 | Dec 31, 2008 | $1.55M | Feb 28, 2011 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $564.10M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $531.10M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $542.80M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $515.10M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $417.60M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $359.80M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $370.50M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $333.37M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $324.97M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $316.77M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.81B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.41B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.54B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.15B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.01B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $1.07B | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $984.10M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $832.78M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $644.68M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $644.59M | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $677.70M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $603.50M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $872.60M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $612.60M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $451.30M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $362.20M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $384.10M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $469.09M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $459.57M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $350.15M | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.70B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $17.10B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $14.55B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $14.23B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $13.68B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $11.69B | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $10.65B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $9.83B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $9.50B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $8.47B | Feb 26, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.15B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $8.96B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $7.04B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $7.28B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $7.11B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $5.66B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $5.03B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $4.63B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $4.54B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $3.90B | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.53B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $8.12B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $7.48B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $6.93B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $6.55B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $6.03B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $5.62B | Feb 25, 2021 |
| FY2020 | Dec 31, 2018 | $5.20B | Feb 25, 2021 |
| FY2020 | Dec 31, 2017 | $4.97B | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $4.57B | Feb 26, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.78B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.79B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $3.53B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $3.69B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $3.70B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $3.17B | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $3.17B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $3.17B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $3.12B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $3.09B | Feb 26, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.59B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $5.21B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $4.62B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $4.11B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $3.75B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $3.27B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $2.90B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $2.44B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $2.18B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $1.77B | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $183.30M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $559.70M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $931.10M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $161.40M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $235.00M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.20B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $271.59M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $40.04M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $141.65M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $258.99M | Feb 27, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.36B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $5.31B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $3.88B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $3.88B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $3.88B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $3.29B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $2.78B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $2.78B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $2.85B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $1.98B | Feb 27, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 6 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 1 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 1 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 25, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 6 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 6 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 1 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 1 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 25, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 130.60M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 132.10M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 132.10M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | 132.90M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 132.70M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | 132.50M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 132.37M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 131.76M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 132.32M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 132.34M | Feb 27, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $259.80M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $244.40M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $228.40M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $212.60M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $196.40M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $180.20M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $164.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $148.11M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $132.34M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $106.33M | Feb 26, 2019 |